FAQ #1 –
When should NGS testing be ordered in cancer patients?
NCCN guidelines strongly recommend broad-panel Next-Generation Sequencing (NGS) to identify actionable genomic alterations in advanced, metastatic, or high-risk cancers, particularly for NSCLC, breast, and gastrointestinal tumors
FAQ #2 –
What is the clinical utility of NGS in oncology?
Next-generation sequencing (NGS) provides high clinical utility in precision medicine by simultaneously analyzing multiple genes to guide targeted therapy, identify hereditary cancer risks, and monitor treatment response. It enables personalized care in oncology by identifying actionable mutations, improving survival in selected patients
FAQ #3 –
Which cancers benefit most from NGS testing?
Key cancer types include non-small cell lung cancer (NSCLC), cholangiocarcinoma, prostate cancer, ovarian cancer, colorectal cancer, advanced breast cancer, thyroid cancer, sarcoma, gastrointestinal stromal tumors (GIST), and cancers of unknown primary